Rua Bioscience reports significant revenue increase

Rua Bioscience has reported a significant increase in revenue for the 2025 financial year.

The company's annual report revealed that revenue reached $1.9 million, up from $320,000 in the previous year.

This growth was attributed to strong sales in key global markets, including Australia, New Zealand, Germany, the United Kingdom, and Czechia.

Rua's loss before tax also decreased to $3.46m, compared to $13.72m in FY24.

However, the company warned that it will require additional capital to support its ongoing growth and meet its minimum expenditure commitments.

Rua Bioscience's board is currently working with key shareholders and advisors on capital raise options.

The company expects sales momentum to continue in the 2026 financial year.